Protocol of a phase II study to evaluate the efficacy and safety of deep-inspiration breath-hold daily online adaptive radiotherapy for centrally located lung tumours (PUDDING study)

Table 2 Dose constraints for OARs

OARs	Indices	Dose (Gy)	Toxicities for endpoints
Spinal cord	Max (D_0.03cc)	33.5	Myelitis
Ipsilateral brachial plexus	Max (D_0.03cc)	40	Neuropathy
Skin*	Max (D_0.03cc)	40	Skin ulcer
Oesophagus	< 5 cc	40	Stenosis/fistula
Heart/Pericardium	< 15 cc	40	Pericarditis
Aorta	< 10 cc	58	Aneurysm
Pulmonary artery	< 1 cc	54.5	Aneurysm
	< 10 cc	47.5
Superior vena cava, pulmonary vein	< 1 cc	48	Stenosis/Fistula
Trachea/Bronchus	< 10 cc	54.5	Stenosis/Fistula
Lungs (Bilateral lungs-PTV)*	V_20Gy < 20%	–	Pneumonia
Stomach and intestines^†	Max (D_0.03cc)	45	Bleeding/Ulcer/Fistula
	< 10 cc	40

OAR organs at risk; PTV planning target volume; V_20Gy percentage of OAR volume receiving 20 Gy or more
*Indices and doses are calculated based on the planning organ at risk for each organ, except for the lungs and skin
^†Dose constraints for stomach and intestines are determined based on SUNSET trial [15]

ISSN: 1748-717X